翻訳と辞書 |
Permeon Biologics : ウィキペディア英語版 | Permeon Biologics
Permeon Biologics, Inc. is a privately held pharmaceutical and biotechnology company in Cambridge, Massachusetts. Founded in 2011 by Harvard chemist David R. Liu and Noubar Afeyan, CEO of Flagship Ventures, the company’s develops a class of proteins, under the trademark Intraphilin™, that enable the transport of large molecules such as antibodies into cells, thereby potentially enabling new classes of intracellular therapies.〔Brian Gormley, ("Flagship Ventures Hatches Two More Health-Care Companies" ), The Wall Street Journal (March 17, 2011)〕〔James J. Cronican, Kevin T. Beier, Tina N. Davis, Jen-Chieh Tseng, Weida Li, David B. Thompson, Allen F. Shih, Erin M. May, Constance L. Cepko, Andrew L. Kung, Qiao Zhou, and David R. Liu ("A Class of Human Proteins That Deliver Functional Proteins Into Mammalian Cells In Vitro and In Vivo" ), Chem Biol, 2011 July 29, 18(7), 833–838〕 ==Ownership== Permeon Biologics closed a Series A financing in November, 2010, with Flagship Ventures of Cambridge, Massachusetts, and ARCH Venture Partners of Chicago.〔Permeon Biologics, ("Investors" )〕
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Permeon Biologics」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|